AMGN
Amgen Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+24/100
Last price
401.53
▼ 1.45 (0.36%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
401.61
Prev close
402.98
Day high
405.00
Day low
396.01
Volume
2.04M
Market cap
$217.66B
P/E (TTM)
25.01
52W range
288.00 – 447.03
Day trading desk
Gap from prior close
-0.34%
Prior close 402.98
VWAP
401.66
-0.03% from price
Relative volume
0.53×
Quiet session
Session range
3.74%
396.01 – 410.81
Position in range
37%
Mid range
ATR (14D)
9.96
2.48% of price
Prior day high
403.69
PDH
Prior day low
397.03
PDL
Bid / ask spread
—
Quote not published
Session volume
1.45M
Avg 2.72M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.97%
-6.9%
1M
-7.92%
-9.1%
3M
+9.41%
+4.9%
6M
+18.41%
+0.2%
YTD
+23.00%
+8.8%
1Y
+35.15%
+18.7%
3Y
+49.80%
-32.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AMGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+38.73K
Net buying
Buy transactions
32
50.08K shares
Sell transactions
4
11.35K shares
Net transactions
+36
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
1.23M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | KHOSLA RACHNA Officer |
SELL | 3.25K | $1.35M | Direct |
| Aug 13, 26 | KHOSLA RACHNA Officer |
CONVERSION | 1.25K | $203.57K | Direct |
| Aug 7, 26 | BUSCH MATTHEW C. Officer |
STOCK | 730 | $0 | Direct |
| Aug 7, 26 | DRAKE MICHAEL V Director |
STOCK | 63 | $0 | Direct |
| Aug 7, 26 | ISHRAK OMAR SYED Director |
STOCK | 85 | $0 | Direct |
| Aug 7, 26 | HOLLEY CHARLES M JR Director |
STOCK | 103 | $0 | Direct |
| Aug 6, 26 | GRYGIEL NANCY A Officer |
SELL | 2.97K | $1.19M | Direct |
| Aug 6, 26 | MILLER DEREK Officer |
SELL | 3.89K | $1.57M | Direct |
| Aug 6, 26 | GRYGIEL NANCY A Officer |
CONVERSION | 2.97K | $526.91K | Direct |
| Aug 6, 26 | MILLER DEREK Officer |
CONVERSION | 3.89K | $659.57K | Direct |
| May 19, 26 | AUSTIN WANDA M Director |
STOCK | 665 | $0 | Direct |
| May 19, 26 | DRUKER BRIAN J Director |
STOCK | 665 | $0 | Direct |
| May 19, 26 | KLOTMAN MARY E Director |
STOCK | 665 | $0 | Direct |
| May 19, 26 | DRAKE MICHAEL V Director |
STOCK | 665 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRADNER JAMES E. |
Officer | 30.46K | Stock Award(Grant) |
BRADWAY ROBERT A |
Chief Executive Officer | 657.30K | Stock Award(Grant) |
ECKERT ROBERT ANDREW |
Director | 26.25K | Stock Award(Grant) |
GORDON MURDO |
Officer | 51.84K | Stock Award(Grant) |
GRAHAM JONATHAN P |
General Counsel | 40.21K | Stock Award(Grant) |
GRIFFITH PETER H. |
Chief Financial Officer | 50.71K | Stock Award(Grant) |
JACKS TYLER |
Director | 18.28K | Stock Award(Grant) |
KULLMAN ELLEN JAMISON |
Director | 14.54K | Stock Award(Grant) |
REESE DAVID M. |
Chief Technology Officer | 42.81K | Stock Award(Grant) |
SANTOS ESTEBAN |
Officer | 84.28K | Stock Award(Grant) |
Fundamentals
Market cap$217.66B
Enterprise value$260.97B
Revenue (TTM)$38.09B
Gross profit$27.39B
EBITDA$17.27B
Net income$8.74B
EPS (TTM)$16.10
Free cash flow$8.65B
Total cash$13.99B
Total debt$57.30B
Book value / share$21.62
Shares outstanding540.63M
Float539.16M
Short % of float2.60%
Dividend yield2.50%
Beta (5Y)0.41
Valuation & profitability ratios
Trailing P/E25.01
Forward P/E16.46
PEG ratio2.43
Price / sales—
Price / book18.62
EV / revenue6.85
EV / EBITDA15.11
Gross margin71.89%
Operating margin35.55%
Profit margin22.95%
Return on equity91.47%
Return on assets8.67%
Debt / equity490.28
Current ratio1.37
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $36.75B | $33.42B | $28.19B | $26.32B | +10.0% |
| Operating revenue | $35.15B | $32.03B | $26.91B | $24.80B | +9.7% |
| Cost of revenue | $12.04B | $12.86B | $8.45B | $6.41B | -6.4% |
| Gross profit | $24.71B | $20.57B | $19.74B | $19.92B | +20.2% |
| Research & development | $7.27B | $5.96B | $4.78B | $4.43B | +21.9% |
| Selling, general & admin | $7.05B | $7.10B | $6.18B | $5.41B | -0.6% |
| Total operating expense | $15.63B | $13.31B | $11.84B | $10.35B | +17.5% |
| Operating income | $9.08B | $7.26B | $7.90B | $9.57B | +25.1% |
| Net interest income | -$2.75B | -$3.15B | -$2.88B | -$1.41B | +12.7% |
| Pre-tax income | $8.98B | $4.61B | $7.86B | $7.35B | +94.7% |
| Tax provision | $1.26B | $519.00M | $1.14B | $794.00M | +143.7% |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | +88.5% |
| Net income to common | $7.71B | $4.09B | $6.72B | $6.55B | +88.5% |
| Basic EPS | 14.33 | 7.62 | 12.56 | 12.18 | +88.1% |
| Diluted EPS | 14.23 | 7.56 | 12.49 | 12.11 | +88.2% |
| EBIT | $11.73B | $7.76B | $10.73B | $8.75B | +51.1% |
| EBITDA | $16.90B | $13.36B | $14.80B | $12.17B | +26.5% |
| Basic shares | 538.00M | 537.00M | 535.00M | 538.00M | +0.2% |
| Diluted shares | 542.00M | 541.00M | 538.00M | 541.00M | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.13B | $11.97B | $10.94B | $7.63B | -23.8% |
| Cash & short-term investments | $9.13B | $11.97B | $10.94B | $9.30B | -23.8% |
| Accounts receivable | $9.57B | $6.78B | $7.27B | $5.56B | +41.1% |
| Inventory | $6.22B | $7.00B | $9.52B | $4.93B | -11.0% |
| Total current assets | $29.06B | $29.03B | $30.33B | $22.19B | +0.1% |
| Property, plant & equipment | $7.91B | $6.54B | $5.94B | $5.43B | +20.9% |
| Goodwill & intangibles | $40.96B | $46.34B | $51.27B | $31.61B | -11.6% |
| Total assets | $90.59B | $91.84B | $97.15B | $65.12B | -1.4% |
| Total current liabilities | $25.49B | $23.10B | $18.39B | $15.69B | +10.3% |
| Current debt | $4.60B | $3.55B | $1.44B | $1.59B | +29.5% |
| Long-term debt | $50.01B | $56.55B | $63.17B | $37.35B | -11.6% |
| Total debt | $54.60B | $60.10B | $64.61B | $38.95B | -9.1% |
| Total liabilities | $81.93B | $85.96B | $90.92B | $61.46B | -4.7% |
| Retained earnings | -$25.11B | -$27.59B | -$26.55B | -$28.62B | +9.0% |
| Shareholder equity | $8.66B | $5.88B | $6.23B | $3.66B | +47.3% |
| Working capital | $3.57B | $5.93B | $11.94B | $6.50B | -39.8% |
| Net tangible assets | -$32.30B | -$40.46B | -$45.04B | -$27.95B | +20.2% |
| Shares issued | 538.80M | 537.00M | 535.40M | 534.00M | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | +88.5% |
| Depreciation & amortisation | $5.17B | $5.59B | $4.07B | $3.42B | -7.6% |
| Stock-based compensation | $494.00M | $530.00M | $431.00M | $401.00M | -6.8% |
| Change in working capital | -$1.98B | $2.37B | -$484.00M | -$733.00M | -183.6% |
| Operating cash flow | $9.96B | $11.49B | $8.47B | $9.72B | -13.3% |
| Capital expenditure | -$1.86B | -$1.10B | -$1.11B | -$936.00M | -69.5% |
| Investing cash flow | -$1.94B | -$1.05B | -$26.20B | -$6.04B | -85.8% |
| Share buybacks | $0 | -$200.00M | $0 | -$6.36B | +100.0% |
| Dividends paid | -$5.12B | -$4.83B | -$4.56B | -$4.20B | -6.0% |
| Financing cash flow | -$10.86B | -$9.41B | $21.05B | -$4.04B | -15.3% |
| Free cash flow | $8.10B | $10.39B | $7.36B | $8.79B | -22.1% |
| End cash position | $9.13B | $11.97B | $10.94B | $7.63B | -23.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $10.05B | $8.62B | $9.87B | $9.56B | $9.18B | +16.7% |
| Operating revenue | $9.54B | $8.22B | $9.37B | $9.14B | $8.77B | +16.1% |
| Cost of revenue | $2.81B | $2.74B | $2.98B | $3.08B | $3.01B | +2.4% |
| Gross profit | $7.24B | $5.87B | $6.89B | $6.47B | $6.17B | +23.3% |
| Research & development | $1.87B | $1.72B | $2.14B | $1.90B | $1.74B | +8.7% |
| Selling, general & admin | $1.75B | $1.60B | $1.95B | $1.72B | $1.69B | +8.9% |
| Total operating expense | $3.73B | $3.21B | $4.17B | $3.95B | $3.51B | +16.2% |
| Operating income | $3.51B | $2.67B | $2.72B | $2.53B | $2.66B | +31.8% |
| Net interest income | -$673.00M | -$657.00M | -$653.00M | -$685.00M | -$694.00M | -2.4% |
| Pre-tax income | $2.77B | $2.08B | $1.51B | $3.92B | $1.57B | +32.8% |
| Tax provision | $393.00M | $265.00M | $181.00M | $705.00M | $136.00M | +48.3% |
| Net income | $2.38B | $1.82B | $1.33B | $3.22B | $1.43B | +30.6% |
| Net income to common | $2.38B | $1.82B | $1.33B | $3.22B | $1.43B | +30.6% |
| Basic EPS | 4.40 | 3.37 | 2.47 | 5.98 | 2.66 | +30.6% |
| Diluted EPS | 4.37 | 3.34 | 2.45 | 5.93 | 2.65 | +30.8% |
| EBIT | $3.44B | $2.74B | $2.17B | $4.61B | $2.26B | +25.5% |
| EBITDA | $4.55B | $3.86B | $3.30B | $5.91B | $3.60B | +18.0% |
| Basic shares | 540.00M | 540.00M | 539.00M | 538.00M | 538.00M | 0.0% |
| Diluted shares | 544.00M | 544.00M | 543.00M | 542.00M | 541.00M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.99B | $12.04B | $9.13B | $9.45B | $8.03B | +16.2% |
| Cash & short-term investments | $13.99B | $12.04B | $9.13B | $9.45B | $8.03B | +16.2% |
| Accounts receivable | $10.23B | $9.14B | $9.57B | $8.49B | $8.70B | +11.9% |
| Inventory | $6.22B | $6.19B | $6.22B | $6.35B | $6.58B | +0.5% |
| Total current assets | $34.96B | $31.48B | $29.06B | $27.89B | $26.73B | +11.1% |
| Property, plant & equipment | $8.55B | $8.22B | $7.91B | $7.22B | $6.86B | +4.0% |
| Goodwill & intangibles | $39.16B | $40.05B | $40.96B | $41.81B | $43.29B | -2.2% |
| Total assets | $95.64B | $92.50B | $90.59B | $90.14B | $87.90B | +3.4% |
| Total current liabilities | $25.50B | $24.95B | $25.49B | $21.79B | $20.48B | +2.2% |
| Current debt | $5.45B | $5.44B | $4.60B | $2.15B | $2.44B | +0.1% |
| Long-term debt | $51.86B | $51.89B | $50.01B | $52.43B | $53.76B | -0.1% |
| Total debt | $57.30B | $57.32B | $54.60B | $54.59B | $56.20B | -0.0% |
| Total liabilities | $83.95B | $83.31B | $81.93B | $80.52B | $80.47B | +0.8% |
| Retained earnings | -$22.27B | -$24.65B | -$25.11B | -$23.80B | -$25.71B | +9.6% |
| Shareholder equity | $11.69B | $9.19B | $8.66B | $9.62B | $7.43B | +27.2% |
| Working capital | $9.46B | $6.52B | $3.57B | $6.09B | $6.26B | +45.1% |
| Net tangible assets | -$27.47B | -$30.86B | -$32.30B | -$32.20B | -$35.86B | +11.0% |
| Shares issued | 540.60M | 539.70M | 538.80M | 538.50M | 538.30M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $2.38B | $1.82B | $1.33B | $3.22B | $1.43B | +30.6% |
| Depreciation & amortisation | $1.11B | $1.12B | $1.13B | $1.31B | $1.34B | -0.4% |
| Stock-based compensation | $165.00M | $75.00M | $125.00M | $127.00M | $157.00M | +120.0% |
| Change in working capital | $408.00M | -$721.00M | -$1.87B | $1.66B | -$759.00M | +156.6% |
| Operating cash flow | $4.00B | $2.19B | $1.60B | $4.68B | $2.28B | +82.8% |
| Capital expenditure | -$513.00M | -$712.00M | -$642.00M | -$436.00M | -$369.00M | +27.9% |
| Investing cash flow | -$569.00M | -$716.00M | -$693.00M | -$414.00M | -$389.00M | +20.5% |
| Dividends paid | -$1.36B | -$1.36B | -$1.28B | -$1.28B | -$1.28B | -0.3% |
| Financing cash flow | -$1.48B | $1.44B | -$1.23B | -$2.85B | -$2.67B | -203.2% |
| Free cash flow | $3.49B | $1.48B | $961.00M | $4.25B | $1.91B | +136.2% |
| End cash position | $13.99B | $12.04B | $9.13B | $9.45B | $8.03B | +16.2% |
Options analytics
Put / call volume
0.36
Call-heavy session
Put / call open interest
0.50
Positioning, not flow
Max pain
400.00
-0.6% from spot
ATM implied vol
40.9%
Nearest strike to spot
Skew (10% OTM)
+5.8%
Puts bid over calls
Call volume
948
Contracts, this expiry
Put volume
339
Contracts, this expiry
Heaviest call OI
420.00
352 contracts
Heaviest put OI
400.00
187 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 5.62 | 6.29 | +12.0% |
| Mar 2026 | 4.77 | 5.15 | +8.0% |
| Dec 2025 | 4.73 | 5.29 | +11.9% |
| Sep 2025 | 5.01 | 5.64 | +12.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 5.78 | 27 | $10.05B | +5.1% |
| Next quarter | 5.80 | 27 | $10.25B | +3.9% |
| Current year | 23.06 | 33 | $38.94B | +5.9% |
| Next year | 24.45 | 33 | $40.31B | +3.5% |
Analyst targets & ownership
Mean target$390.94
High target$500.00
Low target$225.00
Implied upside-2.64%
Analyst count29
ConsensusHOLD
Strong buy / Buy4 / 8
Hold17
Sell / Strong sell3 / 2
Held by insiders0.23%
Held by institutions85.02%
Institutions holding3.99K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
410.59
-2.21% from price
SMA 20
397.97
+1.16% from price
SMA 50
410.55
-1.94% from price
SMA 100
380.78
+5.45% from price
SMA 200
365.31
+10.21% from price
EMA 12
406.50
-1.22% from price
EMA 26
406.40
-1.20% from price
EMA 50
401.86
-0.08% from price
RSI (14)
47.4
Neutral
MACD (12,26,9)
0.10
Hist 0.40
ATR (14)
9.96
2.47% of price
Realised vol 30D
38.5%
Annualised
Bollinger upper
428.92
20, 2σ
Bollinger lower
367.02
20, 2σ
50 / 200 cross
Golden
410.55 vs 365.31
Trend bias
Above 200
+10.21%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.50
Less volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
38.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-16.6%
Peak to trough
Max drawdown 5Y
-26.7%
Peak to trough
ATR 14
9.96
2.47% of price
Beta (reported)
0.41
5Y monthly, from filing
Short interest
Shares short
14.06M
Prior 12.04M
Change vs prior
+16.8%
Shorts adding
% of float
2.60%
Normal
% of shares out
2.60%
Against total outstanding
Days to cover
5.4
Crowded exit
Float
539.16M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Scotiabank | MAINTAINED | Sector Outperform | Sector Outperform |
| Sep 10, 26 | HSBC | DOWNGRADE | Buy | Hold |
| Sep 8, 26 | BMO Capital | DOWNGRADE | Outperform | Market Perform |
| Sep 8, 26 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
| Sep 4, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 20, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 19, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 19, 26 | Argus Research | MAINTAINED | Buy | Buy |
| Aug 18, 26 | Mizuho | MAINTAINED | Neutral | Neutral |
| Aug 18, 26 | Cantor Fitzgerald | MAINTAINED | Neutral | Neutral |
| Aug 14, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 10, 26 | Guggenheim | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate$10.08 / yr
Forward yield2.50%
5-year avg yield3.00%
Payout ratio60.87%
Ex-dividend dateAug 21, 2026
Next pay dateSep 11, 2026
Last split2:1
Split dateNov 22, 1999
SEC filings
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-31
Annual report of employee stock purchase
11-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-05-20
Corporate Changes & Voting Matters
8-K · 2026-05-19
Periodic Financial Reports
10-Q · 2026-05-01
Corporate Changes & Voting Matters
8-K · 2026-04-30
Headlines
2 Nasdaq 100 Stocks Worth Investigating and 1 We Question
StockStory · 12h ago
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks · 13h ago
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
GlobeNewswire · 13h ago
Arboretum Launches to Redefine Precision Medicine for Common Diseases as a Next-Generation Molecular Information Company
Business Wire · 14h ago
Has Eli Lilly Stock Peaked?
Trefis · 1d ago
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Motley Fool · 2d ago
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
Zacks · 5d ago
3 Dow Jones Stocks with Exciting Potential
StockStory · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.